- Global Pharma News & Resources

Global TCR-based Therapies Markets 2021-2030 by Target Indications, Target Antigens, Key Players, Key Geographies, Industry Trends -

DUBLIN--(BUSINESS WIRE)--The "TCR-based Therapies Market by Target Indications, Target Antigens, Key Players and Key Geographies, Industry Trends and Global Forecasts, 2021-2030" report has been added to's offering.

The "TCR-based Therapies Market 2021-2030" report features an extensive study of the current market landscape and future potential of TCR-based therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry.


The inherent heterogeneity of cancer cells and the immunosuppressive properties of the tumor microenvironment make it difficult to design viable and effective therapeutics against oncological disorders. However, targeted cell-based immunotherapies have demonstrated significant potential in treating patients suffering from cancer. Modified T-cell receptor (TCR)-based therapies, an upcoming class of cell-based interventions, is a promising therapeutic modality.

Their tumor-cell killing efficacy may be primarily attributed to the fact that they are pre-sensitized to cancer specific antigens; this enables such interventions to selectively target and eliminate tumor cells from the body of a host, with negligible treatment-related side effects. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various hematological cancers and solid tumors.

Similar to other T-cell based interventions (such as CAR-T cells and TILs), TCR therapies are designed to target the underlying causes (or primary mediators) of a clinical condition. Additionally, this emerging class of biologics is believed to possess the potential to cater to unmet pharmacological needs across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate.

The contemporary TCR-based therapies market is characterized by a healthy and growing pipeline of close to 150 candidate therapies. More than 15 such therapies, including GSK3377794 (GlaxoSmithKline), IMCgp100 (Immunocore), YT-E001 (China Immunotech Biotechnology) and ADP-A2M4 (Adaptimmune Therapeutics), are in the advanced stages of development.

Presently, more than 100 industry and non-industry players, across the globe claim to be engaged in the development and clinical evaluation of antigen sensitized TCR-based cell therapies. The growing interest in this field is reflected in the notable increase in partnership activity (close to 120 deals inked in the past decade alone; CAGR 29%), between various industry players and academic / research institutes. Mostly driven by the need for effective treatment options for cancer, the TCR-based therapy pipeline is expected to continue to steadily grow over the coming years.

Moreover, clinical success is likely to draw in investments that will support ongoing and anticipated therapy development initiatives. Overall, we are led to believe that the global TCR-based therapies market is poised to witness significant growth in the foreseen future.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for TCR-based therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2021-2030.

The report also includes likely sales forecasts of TCR-based therapies that are in the mid- to late stages of development.

Additionally, it features market size projections for the overall TCR-based therapies market, wherein both the current and upcoming opportunity is segmented across:

  • [A] Target indications (bladder cancer, multiple myeloma, ovarian cancer, nasopharyngeal carcinoma, acute myeloid leukemia and sarcoma)
  • [B] Target antigens (NY-ESO-1, p53, WT-1 and EBV)
  • [C] Key players (GlaxoSmithKline, Adaptimmune Therapeutics, Merck, Altor Bioscience, Juno Therapeutics and Takara Bio)
  • [D] Key geographies (North America, Europe, Asia Pacific)

Key Questions Answered

  • What are the prevalent R&D trends related to TCR-based therapies?
  • What are the key therapeutic areas for which TCR-based therapies are being / have been developed?
  • What are the challenges commonly faced by stakeholders engaged in this domain?
  • Who are the leading industry and non-industry players engaged in the development of TCR-based therapies?
  • Across which geographies, extensive research related to TCR-based therapies is being conducted?
  • Who are the key investors in this domain?
  • Who are the key opinion leaders / experts engaged in this upcoming field of therapeutics?
  • What type of partnership models are commonly adopted by industry stakeholders?
  • Across which regions is contract manufacturing support available for TCR-based therapies?
  • Which type of promotional strategies are likely to be adopted for TCR-based therapies that are approved or likely to be commercialized in the future?
  • Which factors are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Emerging Trends On Social Media

5. Market Landscape

6. Popular Target Antigen Analysis

7. Key Opinion Leaders Analysis

8. Tcr-Based Therapy Profiles

9. Key Therapeutic Areas For Tcr-Based Therapies

10. Partnerships And Collaborations

11. Funding And Investment Analysis

12. Case Study: Cell Therapy Manufacturing

13. Cost Price Analysis

14. Market Sizing And Opportunity Analysis

15. Promotional Analysis

16. Company Profiles

17. Concluding Remarks

18. Executive Insights

19. Appendix 1: Tabulated Data

20. Appendix 2: List Of Companies And Organizations

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 13-Jul-2021